Edingen-Neckarhausen, Germany

Jan-Peter Mittwollen

This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignee: Basf Se Corporation. Active years: 2013.


% Patents Active = 100.0


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jan-Peter Mittwollen: Innovator in Pharmaceutical Formulations

Introduction

Jan-Peter Mittwollen is a notable inventor based in Edingen-Neckarhausen, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of rapidly disintegrating tablets. His innovative work has led to the creation of a unique pharmaceutical formulation that enhances the efficiency of drug delivery.

Latest Patents

Jan-Peter Mittwollen holds 1 patent for his invention titled "Pharmaceutical formulation for producing rapidly disintegrating tablets." This patent focuses on a formulation in the form of agglomerates, which is designed to improve the disintegration and absorption of medications.

Career Highlights

Throughout his career, Jan-Peter has been associated with BASF SE Corporation, a leading global chemical company. His role at BASF has allowed him to leverage his expertise in pharmaceutical formulations, contributing to advancements in the industry.

Collaborations

Jan-Peter has collaborated with several talented professionals, including Marcus Wichtner and Michael Schönherr. These collaborations have fostered a creative environment that encourages innovation and the development of new pharmaceutical solutions.

Conclusion

Jan-Peter Mittwollen's contributions to pharmaceutical formulations exemplify the impact of innovation in healthcare. His work continues to influence the development of effective drug delivery systems, showcasing the importance of research and collaboration in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…